Eitan Friedman

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5623686/eitan-friedman-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212 papers	9,264 citations	41 h-index	92 g-index
222 ext. papers	11,014 ext. citations	6.9 avg, IF	4.94 L-index

#	Paper	IF	Citations
212	Abstract P2-09-16: Clinicopatological features and outcome of breast cancer in CHEK2 germline mutation carriers. *Cancer Research*, **2022**, 82, P2-09-16-P2-09-16	10.1	
211	Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants.. *Molecular Genetics & Genomic Medicine*, **2022**, e1928	2.3	
210	Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant. *Familial Cancer*, **2021**, 1	3	0
209	Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. *Familial Cancer*, **2021**, 20, 189-194	3	
208	Re-evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant. *Human Mutation*, **2021**, 42, 592-599	4.7	1
207	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *European Journal of Cancer*, **2021**, 146, 30-47	7.5	15
206	Risk-reducing salpingo-oophorectomy and breast cancer incidence among BRCA-mutation carriers.. *Journal of Clinical Oncology*, **2021**, 39, 10548-10548	2.2	
205	Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population. *Cancer*, **2021**, 127, 3599-3604	6.4	0
204	Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications. *Breast Cancer Research and Treatment*, **2021**, 188, 685-694	4.4	0
203	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
202	Genetic testing for assessment of lynch syndrome in young patients with polyps. *Digestive and Liver Disease*, **2021**, 53, 1640-1646	3.3	
201	Genetic association of the PERIOD3 (PER3) Clock gene with extreme obesity. *Obesity Research and Clinical Practice*, **2021**, 15, 334-338	5.4	1
200	Common Susceptibility Loci for Male Breast Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 453-461	9.7	4
199	Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 1332-1340	4	4
198	Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2021**, 185, 391-399	4.4	2
197	Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations. *Breast Cancer Research and Treatment*, **2021**, 186, 259-263	4.4	0
196	Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients. *Breast Journal*, **2021**, 27, 441-447	1.2	0

195	Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. *Fertility and Sterility*, **2021**, 116, 538-545	4.8	0
194	The spectrum of tumors harboring BAP1 gene alterations. *Cancer Genetics*, **2021**, 256-257, 31-35	2.3	3
193	COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases. *Academic Radiology*, **2021**, 28, 1191-1197	4.3	8
192	Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.. *JAMA Network Open*, **2021**, 4, e2139670	10.4	0
191	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
190	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
189	Germline Mutations in Familial Papillary Thyroid Cancer. *Endocrine Pathology*, **2020**, 31, 14-20	4.2	8
188	Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 353-359	4	5
187	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
186	Germline variant in is a novel candidate gene in familial pheochromocytoma. *Genetical Research*, **2020**, 102, e3	1.1	2
185	Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study. *Cancer Biomarkers*, **2020**, 28, 269-273	3.8	3
184	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. *Nature Genetics*, **2020**, 52, 494-504	36.3	39
183	Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. *Genes Chromosomes and Cancer*, **2020**, 59, 503-516	5	4
182	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
181	De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer. *Familial Cancer*, **2020**, 19, 193-196	3	1
180	Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention. *Menopause*, **2020**, 27, 82-87	2.5	0
179	Long-term remission of disseminated parathyroid cancer following immunotherapy. *Endocrine*, **2020**, 67, 204-208	4	6
178	Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?. *Breast* , **2020**, 49, 81-86	3.6	7

177	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
176	Clinical Characteristics and Prognosis of Gastric Cancer Patients with Germline Mutations: Report of Ten Cases and a Literature Review. *OncoTargets and Therapy*, **2020**, 13, 11637-11644	4.4	4
175	Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. *Breast Cancer Research and Treatment*, **2020**, 181, 445-453	4.4	2
174	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
173	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
172	The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. *Human Mutation*, **2019**, 40, e1-e23	4.7	14
171	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
170	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
169	Molecular and immunohistochemical analyses of uveal melanoma patient cohort. *Melanoma Research*, **2019**, 29, 248-253	3.3	3
168	Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. *Breast Cancer Research and Treatment*, **2019**, 176, 165-170	4.4	4
167	The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. *Breast Cancer Research and Treatment*, **2019**, 178, 231-237	4.4	6
166	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. *Movement Disorders*, **2019**, 34, 1392-1398	7	15
165	Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection. *Molecular and Cellular Proteomics*, **2019**, 18, 865-875	7.6	25
164	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
163	Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. *Cancer*, **2019**, 125, 698-703	6.4	16
162	The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients. *Cancer Causes and Control*, **2019**, 30, 97-101	2.8	2
161	Genetic Analysis of Brazilian Patients with Gallbladder Cancer. *Pathology and Oncology Research*, **2019**, 25, 811-814	2.6	1
160	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138

159	Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. *International Journal of Cancer*, **2018**, 143, 179-183	7.5	11
158	Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic. *Clinical Breast Cancer*, **2018**, 18, e695-e698	3	2
157	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. *European Journal of Human Genetics*, **2018**, 26, 382-386	5.3	10
156	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. *British Journal of Cancer*, **2018**, 118, 266-276	8.7	9
155	Are VNTRs co-localizing with breast cancer-associated SNPs?. *Breast Cancer Research and Treatment* , **2018**, 168, 277-281	4.4	1
154	Mutational analysis of candidate genes in Israeli male breast cancer cases. *Breast Cancer Research and Treatment*, **2018**, 170, 399-404	4.4	4
153	The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel. *Breast Cancer Research and Treatment*, **2018**, 167, 697-702	4.4	7
152	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
151	Accuracy of Risk Prediction Models for Breast Cancer and Mutation Carrier Probabilities in Israel. *Anticancer Research*, **2018**, 38, 4557-4563	2.3	0
150	Trends in the incidence of primary brain, central nervous system and intracranial tumors in Israel, 1990-2015. *Cancer Epidemiology*, **2018**, 56, 6-13	2.8	7
149	The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. *Breast Cancer Research and Treatment*, **2018**, 172, 151-157	4.4	9
148	Co-occurrence of p.Gly111fs and p.Arg16His Variants in Familial MEN1 Phenotype. *Anticancer Research*, **2018**, 38, 3683-3687	2.3	1
147	Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma. *In Vivo*, **2018**, 32, 1527-1531	2.3	4
146	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. *Oncologist*, **2017**, 22, 804-810	5.7	65
145	Differential analysis of mutations in the Jewish population and their implications for diseases. *Genetical Research*, **2017**, 99, e3	1.1	5
144	Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers. *Journal of Genetic Counseling*, **2017**, 26, 1070-1079	2.5	6
143	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
142	Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. *Carcinogenesis*, **2017**, 38, 1112-1118	4.6	11

141	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. *Seminars in Oncology*, **2017**, 44, 187-197	5.5	60
140	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
139	Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. *Breast Cancer Research and Treatment*, **2017**, 166, 881-885	4.4	8
138	The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. *Phytotherapy Research*, **2017**, 31, 1607-1613	6.7	13
137	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
136	De novo mutation in MEN1 is not associated with parental somatic mosaicism. *Endocrine-Related Cancer*, **2017**, 24, L1-L3	5.7	2
135	Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. *Journal of Gynecologic Oncology*, **2017**, 28, e61	4	7
134	Primary Peritoneal Serous Carcinoma in Men: A Rare and Non--associated Entity. *Anticancer Research*, **2017**, 37, 3069-3072	2.3	5
133	Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers. *Israel Medical Association Journal*, **2017**, 19, 365-367	0.9	6
132	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
131	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. *Journal of Clinical Oncology*, **2016**, 34, e61-7	2.2	6
130	The genetic history of Cochin Jews from India. *Human Genetics*, **2016**, 135, 1127-43	6.3	8
129	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
128	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
127	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
126	Cutaneous malignant melanoma and Parkinson disease: Common pathways?. *Annals of Neurology*, **2016**, 80, 811-820	9.4	25
125	The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. *Cancer Genetics*, **2016**, 209, 283-4	2.3	1
124	The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. *Cancer Genetics*, **2016**, 209, 70-4	2.3	21

123	Second international consensus guidelines for breast cancer in young women (BCY2). *Breast*, **2016**, 26, 87-99	3.6	84
122	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
121	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. *Journal of Investigative Dermatology*, **2016**, 136, 1066-1069	4.3	9
120	Functional polymorphisms in the P2X7 receptor gene are associated with stress fracture injury. *Purinergic Signalling*, **2016**, 12, 103-13	3.8	23
119	Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. *Breast Cancer Research and Treatment*, **2016**, 155, 133-8	4.4	14
118	Lessons learned--resolving the enigma of genetic factors in IBS. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 77-87	24.2	55
117	The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. *Cancer Genetics*, **2016**, 209, 50-2	2.3	14
116	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. *Journal of Clinical Oncology*, **2016**, 34, 244-244	2.2	
115	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
114	The Genetics of Bene Israel from India Reveals Both Substantial Jewish and Indian Ancestry. *PLoS ONE*, **2016**, 11, e0152056	3.7	12
113	Cell phone use is associated with an inflammatory cytokine profile of parotid gland saliva. *Journal of Oral Pathology and Medicine*, **2016**, 45, 682-686	3.3	8
112	Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. *Neurology: Genetics*, **2016**, 2, e70	3.8	19
111	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
110	Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma. *Cancer Genetics*, **2016**, 209, 251-7	2.3	4
109	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. *Breast Cancer Research and Treatment*, **2016**, 157, 157-65	4.4	36
108	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2016**, 157, 319-327	4.4	22
107	Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers. *Israel Medical Association Journal*, **2016**, 18, 609-612	0.9	1
106	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177

105	Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for BRCA1/2 mutation carriers. *Psycho-Oncology*, **2015**, 24, 726-31	3.9	8
104	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nature Genetics*, **2015**, 47, 987-995	36.3	162
103	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. *Familial Cancer*, **2015**, 14, 383-91	3	23
102	Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. *Fertility and Sterility*, **2015**, 103, 1305-12	4.8	36
101	Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2015**, 150, 631-5	4.4	9
100	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
99	Malignant phenotype and two SDHD mutations in a family with paraganglioma syndrome type 1. *Genetical Research*, **2015**, 97, e3	1.1	3
98	BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. *Fertility and Sterility*, **2015**, 104, 1162-7	4.8	62
97	Genotyping of geographically diverse Druze trios reveals substructure and a recent bottleneck. *European Journal of Human Genetics*, **2015**, 23, 1093-9	5.3	7
96	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
95	Next generation sequencing for newborn screening: are we there yet?. *Genetical Research*, **2015**, 97, e17	1.1	8
94	GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancer. *Genetical Research*, **2015**, 97, e11	1.1	11
93	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
92	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
91	Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. *JAMA Neurology*, **2015**, 72, 58-65	17.2	54
90	DNA Base-Excision Repair Genes OGG1 and NTH1 in Brazilian Lung Cancer Patients. *Molecular Diagnosis and Therapy*, **2015**, 19, 389-95	4.5	4
89	Inter- and intra-lesional molecular heterogeneity of oral leukoplakia. *Oral Oncology*, **2015**, 51, 178-81	4.4	28
88	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156

87	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. *Breast Cancer Research and Treatment*, **2014**, 147, 113-8	4.4	19
86	Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 14205-10	11.5	216
85	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
84	FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns. *Genetical Research*, **2014**, 96, e11	1.1	4
83	Novel candidate genes putatively involved in stress fracture predisposition detected by whole-exome sequencing. *Genetical Research*, **2014**, 96, e004	1.1	7
82	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. *Genetical Research*, **2014**, 96, e002	1.1	15
81	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
80	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers. *Breast Cancer Research and Treatment*, **2013**, 138, 753-60	4.4	27
79	Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. *European Journal of Human Genetics*, **2013**, 21, 212-6	5.3	32
78	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
77	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
76	Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. *Genetical Research*, **2013**, 95, 174-7	1.1	14
75	Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.. *Journal of Clinical Oncology*, **2013**, 31, 278-278	2.2	1
74	Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 131, 981-5	4.4	1
73	Germline mutations in RAD51C in Jewish high cancer risk families. *Breast Cancer Research and Treatment*, **2012**, 136, 869-74	4.4	11
72	Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. *Familial Cancer*, **2012**, 11, 483-91	3	27
71	The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. *Familial Cancer*, **2012**, 11, 243-7	3	7
70	Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?. *Breast Cancer Research and Treatment*, **2012**, 132, 669-73	4.4	6

69	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 132, 1119-26	4.4	7
68	Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. *Breast Cancer Research and Treatment*, **2012**, 133, 1153-7	4.4	18
67	Candidate gene analysis in israeli soldiers with stress fractures. *Journal of Sports Science and Medicine*, **2012**, 11, 147-55	2.7	11
66	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 126, 521-7	4.4	3
65	Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. *Breast Cancer Research and Treatment*, **2011**, 127, 489-95	4.4	24
64	Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. *Breast Cancer Research and Treatment*, **2011**, 129, 557-63	4.4	17
63	Androgen receptor CAG repeat size is associated with stress fracture risk: a pilot study. *Clinical Orthopaedics and Related Research*, **2011**, 469, 2925-31	2.2	11
62	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
61	BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. *International Journal of Gynecological Cancer*, **2010**, 20, 1148-53	3.5	31
60	Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. *American Journal of Human Genetics*, **2010**, 86, 850-9	11	181
59	The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. *Gynecologic Oncology*, **2010**, 119, 511-5	4.9	18
58	Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. *International Journal of Cancer*, **2010**, 127, 589-97	7.5	104
57	Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2009**, 116, 195-200	4.4	32
56	Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. *Familial Cancer*, **2009**, 8, 127-33	3	11
55	SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women. *Familial Cancer*, **2009**, 8, 135-44	3	4
54	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. *Familial Cancer* , **2009**, 8, 473-8	3	5
53	Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals. *Genetic Testing and Molecular Biomarkers*, **2009**, 13, 465-9	1.6	9
52	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4340-5	11.5	256

51	A novel MSH2 germline mutation in a Druze HNPCC family. *Familial Cancer*, **2008**, 7, 135-9	3	2
50	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. *International Journal of Cancer*, **2008**, 122, 2017-22	7.5	268
49	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
48	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. *Gynecologic Oncology*, **2007**, 104, 7-10	4.9	116
47	Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. *Cancer Letters*, **2007**, 257, 236-43	9.9	74
46	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
45	Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. *Israel Medical Association Journal*, **2007**, 9, 791-6	0.9	10
44	Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3770-4	11.5	74
43	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Research*, **2006**, 8, R15	8.3	40
42	The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. *Genetic Testing and Molecular Biomarkers*, **2006**, 10, 200-7		6
41	Genotype phenotype correlations in Israeli colorectal cancer patients. *International Journal of Cancer*, **2005**, 114, 58-73	7.5	35
40	Colonic Adenomas Do Not Cosegregate with the I1307K APC Missense Mutation in an Israeli Non-Ashkenazi Family. *Digestive Diseases and Sciences*, **2005**, 50, 52-55	4	0
39	Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like families. *Familial Cancer*, **2005**, 4, 291-4	3	7
38	Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients. *Human Mutation*, **2004**, 23, 399-400	4.7	31
37	CHEK2*1100delC and male breast cancer risk in Israel. *International Journal of Cancer*, **2004**, 108, 479-80	7.5	41
36	The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. *Familial Cancer*, **2004**, 3, 11-4	3	6
35	Genetic analysis of familial colorectal cancer in Israeli Arabs. *Human Mutation*, **2003**, 21, 446-7	4.7	27
34	Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information. *American Journal of Medical Genetics Part A*, **2002**, 111, 147-51		16

33	Mutational analysis of the hMSH6 gene in familial and early-onset colorectal and endometrial cancer in Israeli patients. *Genetic Testing and Molecular Biomarkers*, **2002**, 6, 323-6		3
32	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2002**, 94, 1773-9	9.7	266
31	Bloom syndrome and Fanconi anemia: rate and ethnic origin of mutation carriers in Israel. *Israel Medical Association Journal*, **2002**, 4, 95-7	0.9	20
30	The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. *Cancer*, **2001**, 92, 1190-4	6.4	22
29	Adrenal tumors in BRCA1/BRCA2 mutation carriers. *American Journal of Medical Genetics Part A*, **2001**, 98, 277-9		8
28	The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. *Genetic Testing and Molecular Biomarkers*, **2001**, 5, 141-6		22
27	Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. *Circulation*, **2001**, 103, 2822-7	16.7	217
26	Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. *New England Journal of Medicine*, **2001**, 345, 235-40	59.2	320
25	The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. *Public Health Genomics*, **2001**, 4, 50-55	1.9	21
24	The m2 and m4 polymorphisms in CYP1A1 by NcoI digest-revision of detection method. *Human Mutation*, **2000**, 15, 120	4.7	1
23	Prenatal diagnosis of a novel COL1A1 mutation in osteogenesis imperfecta type I carried through full term pregnancy. *Prenatal Diagnosis*, **2000**, 20, 876-80	3.2	12
22	Mutation analysis of the MEN1 gene in Israeli patients with MEN1 and familial isolated hyperprolactinemia. *Human Mutation*, **2000**, 16, 269	4.7	5
21	Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. *Human Mutation*, **2000**, 16, 491-501	4.7	48
20	Prophylactic oophorectomy: clinical considerations. *Journal of Surgical Oncology*, **2000**, 19, 20-7		13
19	Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. *European Journal of Human Genetics*, **2000**, 8, 590-6	5.3	22
18	p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2000**, 107, 849-54	3.7	10
17	Genetic analyses of male breast cancer in Israel. *Genetic Testing and Molecular Biomarkers*, **2000**, 4, 313-7		26
16	The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. *Genetic Testing and Molecular Biomarkers*, **2000**, 4, 403-7		6

15	Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews. *European Journal of Human Genetics*, **1999**, 7, 555-9	5.3	16
14	Mutational analyses of candidate genes in human squamous cell carcinomas. *Laryngoscope*, **1999**, 109, 661-3	3.6	5
13	A neutral polymorphism (c1088C>T) in the estrogen receptor detected by DGGE. *Human Mutation*, **1999**, 13, 507-507	4.7	
12	Molecular analyses of the vasopressin type 2 receptor and aquaporin-2 genes in Brazilian kindreds with nephrogenic diabetes insipidus. *Human Mutation*, **1999**, 14, 233-9	4.7	15
11	A germline mutation in the von Hippel-Lindau disease gene (L178Q) detected by denaturing gradient gel electrophoresis in a large Jewish-Yemenite family. *Human Mutation*, **1999**, 14, 448	4.7	1
10	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). *European Journal of Human Genetics*, **1998**, 6, 176-80	5.3	10
9	Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer disease brains. *Journal of Neurogenetics*, **1998**, 12, 55-65	1.6	8
8	Comparative genomic hybridization analysis of nonfunctioning pituitary tumors. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1801-5	5.6	42
7	Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. *Clinical Endocrinology*, **1997**, 47, 707-12	3.4	32
6	Exclusion of the phosphoinositide-specific phospholipase C beta 3 (PLCB3) gene as a candidate for multiple endocrine neoplasia type 1. *Human Genetics*, **1997**, 99, 130-2	6.3	5
5	Could the 185delAG BRCA1 Mutation Be an Ancient Jewish Mutation?. *European Journal of Human Genetics*, **1997**, 5, 413-416	5.3	28
4	Malignant peritoneal mesothelioma: long-term spontaneous clinical remission. *Medical and Pediatric Oncology*, **1991**, 19, 325-8		6
3	Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. *New England Journal of Medicine*, **1991**, 325, 1688-95	59.2	1530
2	Non-Hodgkin lymphoma complicating acute lymphoblastic leukemia in remission. *Medical and Pediatric Oncology*, **1988**, 16, 132-4		7
1	Streptococcus bovis bacteremia and underlying gastrointestinal neoplasms. *Medical and Pediatric Oncology*, **1986**, 14, 313-5		6